REPH - レクロ・ファ―マ (Recro Pharma Inc.) レクロ・ファ―マ

 REPHのチャート


 REPHの企業情報

symbol REPH
会社名 Recro Pharma Inc (レクロ・ファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 レクロ・ファーマ(Recro Pharma Inc.)臨床段階の製薬会社である。同社は病院用及び外来ケア施設向けに急性疼痛の治療のための非オピオイド製品の開発に従事する。同社のリード候補製品は、メロキシカムの注射可能な形態である。疼痛適応症の候補製品には、急性術後疼痛の治療のための開発候補製品である注射可能なメロキシカム、術後疼痛の治療のための開発中の製品候補Dex-IN、及び慢性疼痛の治療のための製品候補であるDex-SLとFado(Fadolmidine)が含まれる。Fadoは、手術または特定の種類の慢性疼痛に関連する痛みのために脊椎に注射することによって使用される候補製品であり、糖尿病患者に起こりうる局所組織(神経障害)、特に下肢の神経損傷に関連する重篤な痛みを治療するための局所適用のための製品である。   レクロ・ファ―マは米国の臨床段階の特殊医薬品会社。術後疼痛のための非オピオイド治療薬を開発。主要製品のデックズ-INは、術後疼痛の治療や癌突出痛の治療のための開発中の製品候補で、デックズ-SLは、慢性疼痛の治療のために開発する製品候補。本社はペンシルベニア州。   Recro Pharma, Inc. is a pharmaceutical company, which engages in the research and development of non-opioid therapeutics for the treatment of acute post operative pain. It operates through the Acute Care, and Contract Development and Manufacturing (CDMO) business segment. The Acute Care segment focuses on developing innovative products for hospital and related settings. The CDMO segment leverages the company's formulation expertise to develop and manufacture pharmaceutical products using the company's proprietary delivery technologies for commercial partners who commercialize or plan to commercialize these products. Its products include Meloxicam, Dexmedetomidine, and Fadolmidine. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Malvern, PA.
本社所在地 490 Lapp Road Malvern PA 19355 USA
代表者氏名 Wayne B. Weisman ウェイン・B・ワイズマン
代表者役職名 Independent Chairman of the Board
電話番号 +1 484-395-2400
設立年月日 39387
市場名 NASDAQ Small Cap
ipoyear 2014年
従業員数 256人
url www.recropharma.com
nasdaq_url https://www.nasdaq.com/symbol/reph
adr_tso
EBITDA EBITDA(百万ドル) -42.25000
終値(lastsale) 6.965
時価総額(marketcap) 144301308.795
時価総額 時価総額(百万ドル) 149.79160
売上高 売上高(百万ドル) 77.43900
企業価値(EV) 企業価値(EV)(百万ドル) 155.19660
当期純利益 当期純利益(百万ドル) -50.40800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Recro Pharma Inc revenues increased 16% to $41.3M. Net loss increased 49% to $25.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Acute Care segment loss increase of 48% to $40M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.89 to -$1.27.

 REPHのテクニカル分析


 REPHのニュース

   The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering  2019/12/20 13:12:05 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 19.) Acceleron Pharma Inc (NASDAQ: XLRN ) Ardelyx Inc (NASDAQ: ARDX ) AstraZeneca plc (NYSE: AZN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) (priced its 2-million-share common stock offering at $87 per share) Clearside Biomedical Inc (NASDAQ: CLSD ) Cortexyme Inc (NASDAQ: CRTX ) Cue Biopharma Inc (NASDAQ: CUE ) Exagen Inc (NASDAQ: XGN ) Globus Medical Inc (NYSE: GMED ) Horizon Therapeutics PLC (NASDAQ: HZNP ) HEALTH SCIENCES/SH (NASDAQ: IMVT ) (The acquisition vehicle announced merger with Immuvant, a clinical-stage biopharma company focusing on autoimmune disorders) IVERIC bio Inc (NASDAQ: ISEE ) Johnson & Johnson (NYSE: JNJ ) (Barclays upgraded shares to Overweight) The Medicines Company (NASDAQ: MDCO ) Merck & Co., Inc. (NYSE: MRK ) Mirum Pharmaceuticals Inc (NASDAQ: MIRM ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Monopar Therapeutics Inc. (NASDAQ: MNPR ) (Went public Thursday) Myokardia Inc (NASDAQ: MYOK ) NeoGenomics, Inc. (NASDAQ: NEO ) Novan Inc (NASDAQ: NOVN ) Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP ) Principia Biopharma Inc (NASDAQ: PRNB ) Quest Diagnostics Inc (NYSE: DGX ) Recro Pharma Inc (NASDAQ: REPH ) Sanofi SA (NASDAQ: SNY ) SpringWorks Therapeutics Inc (NASDAQ: SWTX ) Down In The Dumps (Biotech stocks that hit 52-week lows Dec. 19.) Aethlon Medical, Inc. (NASDAQ: AEMD ) Anixa Biosciences Inc (NASDAQ: ANIX ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Correvio Pharma Corp (NASDAQ: …
   The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug  2019/12/04 12:06:30 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 3) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares Pharma Inc (NASDAQ: ATRS ) Ardelyx Inc (NASDAQ: ARDX )(announced positive results for the Phase 3 study of tenapanor as monotherapy for treating hyperphosphatemia in patients with chronic kidney disease on dialysis) Audentes Therapeutics Inc (NASDAQ: BOLD )( announced a deal to be bought by ASTELLAS PHARMA/ADR (OTC: ALPMY )) Axsome Therapeutics Inc (NASDAQ: AXSM )(announced positive mid-stage readout for drug to treat narcolepsy) Cassava Sciences Inc (NASDAQ: SAVA ) Constellation Pharmaceuticals Inc (NASDAQ: CNST ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) DexCom, Inc. (NASDAQ: DXCM ) Eidos Therapeutics Inc (NASDAQ: EIDX ) ESSA Pharma Inc (NASDAQ: EPIX ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Inspire Medical Systems Inc (NYSE: INSP ) PTC Therapeutics, Inc. (NASDAQ: PTCT ) Recro Pharma Inc (NASDAQ: REPH ) Xenon Pharmaceuticals Inc (NASDAQ: XENE ) Zai Lab Ltd (NASDAQ: ZLAB ) Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. 3) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Evelo Biosciences Inc (NASDAQ: EVLO ) Midatech Pharma PLC-ADR (NASDAQ: MTP ) Neon Therapeutics Inc (NASDAQ: NTGN ) Orgenesis Inc (NASDAQ: ORGS ) Predictive Oncology Inc (NASDAQ: POAI ) Protagonist Therapeutics Inc (NASDAQ: PTGX )(announced results from mid-stage study of PTG-300 in transfusion-dependent beta-thalassemia) Therapix Biosciences …
   The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate  2019/11/22 13:18:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 21.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) (raised full-year guidance following completion of Otezla purchase from Celgene) Antares Pharma Inc (NASDAQ: ATRS ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cue Biopharma Inc (NASDAQ: CUE ) Epizyme Inc (NASDAQ: EPZM ) Kamada Ltd. (NASDAQ: KMDA ) Kodiak Sciences Inc (NASDAQ: KOD ) Molecular Templates Inc (NASDAQ: MTEM ) Recro Pharma Inc (NASDAQ: REPH ) (completed spin-off of Baudax Bio in a bid to a become a pure play CDMO) Down In The Dumps (Biotech stocks that hit 52-week lows on Nov. 21.) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) (received European approval for its Rhokiinsa 0.02% for the reduction of elevated intraocular pressure) Affimed NV (NASDAQ: AFMD ) Anixa Biosciences Inc (NASDAQ: ANIX ) CareDx Inc (NASDAQ: CDNA ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Genprex Inc (NASDAQ: GNPX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Interpace Biosciences Inc (NASDAQ: IDXG ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) (priced its previously announced common stock offering) Iterum Therapeutics PLC (NASDAQ: ITRM ) Jaguar Health Inc (NASDAQ: JAGX ) MacroGenics Inc (NASDAQ: MGNX ) Merrimack Pharmaceuticals Inc (NASDAQ: MACK ) Neon Therapeutics Inc (NASDAQ: NTGN ) (announced a changed focus and the elimination of 24% of workforce) Novavax, Inc. (NASDAQ: NVAX ) Nuvectra Corp (NASDAQ: NVTR ) Onconova Therapeutics …
   Analysts Expect Recro Pharma Inc (NASDAQ:REPH) Will Announce Quarterly Sales of $18.75 Million  2019/11/15 10:00:52 Modern Readers
Analysts expect Recro Pharma Inc (NASDAQ:REPH) to post $18.75 million in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Recro Pharma’s earnings, with estimates ranging from $17.50 million to $20.20 million. Recro Pharma reported sales of $17.78 million in the same quarter last year, which would suggest a positive […]
   The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing  2019/11/14 13:07:04 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 13.) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bausch Health Companies Inc (NYSE: BHC ) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ) (reacted to its third-quarter results) Bristol-Myers Squibb Co (NYSE: BMY ) Celgene Corporation (NASDAQ: CELG ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Edwards Lifesciences Corp (NYSE: EW ) ESSA Pharma Inc (NASDAQ: EPIX ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) (reacted to its third-quarter results) IGM Biosciences Inc (NASDAQ: IGMS ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Opiant Pharmaceuticals Inc (NASDAQ: OPNT ) ( reported an unexpected profit for its third quarter) Recro Pharma Inc (NASDAQ: REPH ) Seattle Genetics, Inc. (NASDAQ: SGEN ): filed an arbitration demand to settle dispute with DAIICHI SANKYO/S ADR (OTC: DSNKY ).
  毎日のバイオテクノロジーパルス:アクソバントは遺伝子療法の研究結果に急増、FDAはメルクのエボラワクチンを承認、アベオナは提供を発表 The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering  2019/12/20 13:12:05 Benzinga
「以下は、過去24時間にわたるバイオテクノロジー分野のトップ開発のまとめです。スケーリングピーク(12週間で52週間の高値に達したバイオテック株)Acceleron Pharma Inc(NASDAQ:XLRN)Ardelyx Inc(NASDAQ:ARDX )AstraZeneca plc(NYSE:AZN)Axsome Therapeutics Inc(NASDAQ:AXSM)(1株あたり87ドルで200万株の普通株を価格設定)Clearside Biomedical Inc(NASDAQ:CLSD)Cortexyme Inc(NASDAQ:CRTX)Cue Biopharma Inc (NASDAQ:CUE)Exagen Inc(NASDAQ:XGN)Globus Medical Inc(NYSE:GMED)Horizon Therapeutics PLC(NASDAQ:HZNP)HEALTH SCIENCES / SH(NASDAQ:IMVT)(買収車両は臨床段階であるImmuvantとの合併を発表しました自己免疫疾患に焦点を当てたバイオ医薬品会社)IVERIC bio Inc(NASDAQ:ISEE)Johnson&Johnson(NYSE:JNJ)(Barclaysは株式をオーバーウェイトにアップグレードしました)The Medicines Company(NASDAQ:MDCO)Merck&Co.、Inc.(NYSE:MRK) Mirum Pharmaceuticals Inc(NASDAQ:MIRM)Momenta Pharmaceuticals、Inc.(NASDAQ:MNTA)Monopar Thera peutics Inc.(NASDAQ:MNPR)(木曜日公開)Myokardia Inc(NASDAQ:MYOK)NeoGenomics、Inc.(NASDAQ:NEO)Novan Inc(NASDAQ:NOVN)Oramed Pharmaceuticals、Inc.(NASDAQ:ORMP)Principia Biopharma Inc( NASDAQ:PRNB)Quest Diagnostics Inc(NYSE:DGX)Recro Pharma Inc(NASDAQ:REPH)Sanofi SA(NASDAQ:SNY)SpringWorks Therapeutics Inc(NASDAQ:SWTX)Down In The Dumps(52週間ぶりの安値に達したバイオテック株) 19.)Aethlon Medical、Inc.(NASDAQ:AEMD)Anixa Biosciences Inc(NASDAQ:ANIX)Aridis Pharmaceuticals Inc(NASDAQ:ARDS)China SXT Pharmaceuticals Inc(NASDAQ:SXTC)Correvio Pharma Corp(NASDAQ:…
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 19.) Acceleron Pharma Inc (NASDAQ: XLRN ) Ardelyx Inc (NASDAQ: ARDX ) AstraZeneca plc (NYSE: AZN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) (priced its 2-million-share common stock offering at $87 per share) Clearside Biomedical Inc (NASDAQ: CLSD ) Cortexyme Inc (NASDAQ: CRTX ) Cue Biopharma Inc (NASDAQ: CUE ) Exagen Inc (NASDAQ: XGN ) Globus Medical Inc (NYSE: GMED ) Horizon Therapeutics PLC (NASDAQ: HZNP ) HEALTH SCIENCES/SH (NASDAQ: IMVT ) (The acquisition vehicle announced merger with Immuvant, a clinical-stage biopharma company focusing on autoimmune disorders) IVERIC bio Inc (NASDAQ: ISEE ) Johnson & Johnson (NYSE: JNJ ) (Barclays upgraded shares to Overweight) The Medicines Company (NASDAQ: MDCO ) Merck & Co., Inc. (NYSE: MRK ) Mirum Pharmaceuticals Inc (NASDAQ: MIRM ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Monopar Therapeutics Inc. (NASDAQ: MNPR ) (Went public Thursday) Myokardia Inc (NASDAQ: MYOK ) NeoGenomics, Inc. (NASDAQ: NEO ) Novan Inc (NASDAQ: NOVN ) Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP ) Principia Biopharma Inc (NASDAQ: PRNB ) Quest Diagnostics Inc (NYSE: DGX ) Recro Pharma Inc (NASDAQ: REPH ) Sanofi SA (NASDAQ: SNY ) SpringWorks Therapeutics Inc (NASDAQ: SWTX ) Down In The Dumps (Biotech stocks that hit 52-week lows Dec. 19.) Aethlon Medical, Inc. (NASDAQ: AEMD ) Anixa Biosciences Inc (NASDAQ: ANIX ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Correvio Pharma Corp (NASDAQ: …
   The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug  2019/12/04 12:06:30 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 3) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares Pharma Inc (NASDAQ: ATRS ) Ardelyx Inc (NASDAQ: ARDX )(announced positive results for the Phase 3 study of tenapanor as monotherapy for treating hyperphosphatemia in patients with chronic kidney disease on dialysis) Audentes Therapeutics Inc (NASDAQ: BOLD )( announced a deal to be bought by ASTELLAS PHARMA/ADR (OTC: ALPMY )) Axsome Therapeutics Inc (NASDAQ: AXSM )(announced positive mid-stage readout for drug to treat narcolepsy) Cassava Sciences Inc (NASDAQ: SAVA ) Constellation Pharmaceuticals Inc (NASDAQ: CNST ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) DexCom, Inc. (NASDAQ: DXCM ) Eidos Therapeutics Inc (NASDAQ: EIDX ) ESSA Pharma Inc (NASDAQ: EPIX ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Inspire Medical Systems Inc (NYSE: INSP ) PTC Therapeutics, Inc. (NASDAQ: PTCT ) Recro Pharma Inc (NASDAQ: REPH ) Xenon Pharmaceuticals Inc (NASDAQ: XENE ) Zai Lab Ltd (NASDAQ: ZLAB ) Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. 3) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Evelo Biosciences Inc (NASDAQ: EVLO ) Midatech Pharma PLC-ADR (NASDAQ: MTP ) Neon Therapeutics Inc (NASDAQ: NTGN ) Orgenesis Inc (NASDAQ: ORGS ) Predictive Oncology Inc (NASDAQ: POAI ) Protagonist Therapeutics Inc (NASDAQ: PTGX )(announced results from mid-stage study of PTG-300 in transfusion-dependent beta-thalassemia) Therapix Biosciences …
   The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate  2019/11/22 13:18:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 21.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) (raised full-year guidance following completion of Otezla purchase from Celgene) Antares Pharma Inc (NASDAQ: ATRS ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cue Biopharma Inc (NASDAQ: CUE ) Epizyme Inc (NASDAQ: EPZM ) Kamada Ltd. (NASDAQ: KMDA ) Kodiak Sciences Inc (NASDAQ: KOD ) Molecular Templates Inc (NASDAQ: MTEM ) Recro Pharma Inc (NASDAQ: REPH ) (completed spin-off of Baudax Bio in a bid to a become a pure play CDMO) Down In The Dumps (Biotech stocks that hit 52-week lows on Nov. 21.) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) (received European approval for its Rhokiinsa 0.02% for the reduction of elevated intraocular pressure) Affimed NV (NASDAQ: AFMD ) Anixa Biosciences Inc (NASDAQ: ANIX ) CareDx Inc (NASDAQ: CDNA ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Genprex Inc (NASDAQ: GNPX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Interpace Biosciences Inc (NASDAQ: IDXG ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) (priced its previously announced common stock offering) Iterum Therapeutics PLC (NASDAQ: ITRM ) Jaguar Health Inc (NASDAQ: JAGX ) MacroGenics Inc (NASDAQ: MGNX ) Merrimack Pharmaceuticals Inc (NASDAQ: MACK ) Neon Therapeutics Inc (NASDAQ: NTGN ) (announced a changed focus and the elimination of 24% of workforce) Novavax, Inc. (NASDAQ: NVAX ) Nuvectra Corp (NASDAQ: NVTR ) Onconova Therapeutics …
   Analysts Expect Recro Pharma Inc (NASDAQ:REPH) Will Announce Quarterly Sales of $18.75 Million  2019/11/15 10:00:52 Modern Readers
Analysts expect Recro Pharma Inc (NASDAQ:REPH) to post $18.75 million in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Recro Pharma’s earnings, with estimates ranging from $17.50 million to $20.20 million. Recro Pharma reported sales of $17.78 million in the same quarter last year, which would suggest a positive […]
   The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing  2019/11/14 13:07:04 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 13.) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bausch Health Companies Inc (NYSE: BHC ) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ) (reacted to its third-quarter results) Bristol-Myers Squibb Co (NYSE: BMY ) Celgene Corporation (NASDAQ: CELG ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Edwards Lifesciences Corp (NYSE: EW ) ESSA Pharma Inc (NASDAQ: EPIX ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) (reacted to its third-quarter results) IGM Biosciences Inc (NASDAQ: IGMS ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Opiant Pharmaceuticals Inc (NASDAQ: OPNT ) ( reported an unexpected profit for its third quarter) Recro Pharma Inc (NASDAQ: REPH ) Seattle Genetics, Inc. (NASDAQ: SGEN ): filed an arbitration demand to settle dispute with DAIICHI SANKYO/S ADR (OTC: DSNKY ).
   Recro Pharma, Inc. (REPH) CEO Geraldine Henwood on Q1 2019 Results - Earnings Call Transcript  2019-05-12
Recro Pharma, Inc. (REPH) Q1 2019 Earnings Conference Call May 10, 2019 08:00 ET Company Participants Claudia Styslinger - IR Geraldine Henwood - President & CEO Ryan Lake - CFO Conference Call Participants Leland Gershell - Oppenheimer & Co. David Amsellem - Pipe…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 レクロ・ファ―マ REPH Recro Pharma Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)